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Microtubule bindingTau is themajormicrotubule-associated protein in neurons involved inmicrotubule stabilization in the axonal com-
partment. Changes in tau gene expression, alternative splicing and posttranslational modiﬁcation regulate tau func-
tion and in tauopathies can result in taumislocalization and dysfunction, causing tau aggregation and cell death. To
uncover proteins involved in the development of tauopathies, a yeast two-hybrid systemwas used to screen for tau-
interacting proteins. We show that axotrophin/MARCH7, a RING-variant domain containing protein with similarity
to E3 ubiquitin ligases interacts with tau.We deﬁned the tau binding domain to amino acids 552–682 of axotrophin
comprising the RING-variant domain. Co-immunoprecipitation and co-localization conﬁrmed the speciﬁcity of the
interaction. Intracellular localization of axotrophin is determined by an N-terminal nuclear targeting signal and a
C-terminal nuclear export signal. In AD brain nuclear localization is lost and axotrophin is rather associated with
neuroﬁbrillary tangles. We ﬁnd here that tau becomes mono-ubiquitinated by recombinant tau-interacting RING-
variant domain,which diminishes itsmicrotubule-binding. In vitro ubiquitination of four-repeat tau results in incor-
poration of up to four ubiquitinmolecules compared to twomolecules in three-repeat tau. In summary,wepresent a
novel tau modiﬁcation occurring preferentially on 4-repeat tau protein which modiﬁes microtubule-binding and
may impact on the pathogenesis of tauopathies.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Tau protein belongs to the family of microtubule-associated proteins
(MAPs) and is predominantly expressed in neurons, where it is enriched
in axons. Tau protein binds to microtubules and promotes their assem-
bly and stabilization. Different tau isoforms generated by alternative
splicing display variable microtubule binding capacities. In the human
brain six isoforms of tau protein, that arise from a single gene by alterna-
tivemRNA splicing of exons 2, 3 and10, are found [1]. Exon 10 encodes a
microtubule binding repeat in the C-terminus in addition to three
microtubule binding repeats existing in all tau isoforms. Exons 2 and 3
encode N-terminal insertions. Over 30 potential phosphorylation sites
are identiﬁed in the tau molecule. Most of these phosphorylation sites
are located in the ﬂanking regions around the microtubule binding
repeats and affect microtubule binding [2,3].
Tau pathology is a deﬁning feature in several neuropathological disor-
ders called tauopathies [4]. They are characterized by tau aggregation intoin Research, Jahnallee 59, 04109
725729.
zer).abnormal, beta-sheet containing ﬁlaments (PHFs) in neural cells and ac-
companied by a loss of axonal subcellular tau compartmentalization, by
tau hyperphosphorylation and by changes in other posttranslational
modiﬁcations. Whereas most tauopathies such as Pick's disease,
corticobasal degeneration, progressive supranuclear palsy and
Alzheimer's disease (AD) are not linked to mutations, frontotemporal
dementia with parkinsonism linked to chromosome 17 is caused by
autosomal dominant mutations in the MAPT gene [4].
Tau protein in its natively unfolded form is hydrophilic, highly solu-
ble and degraded in an ubiquitin independentmanner by the core (20S)
of proteasome [5,6]. The molecular incident responsible for triggering
tau aggregation in sporadic tauopathies is unknown. The tau protein
amino acid (aa) sequences most prone to convert into beta-sheet have
been identiﬁed in the PHF6 and PHF6* sequence [7]. It is assumed that
alterations in charge distribution in these amino acids may play a role
in transition to a secondary structure.
Recent studies implicate that in addition to the tau protein expression
level and turnover aberrant posttranslational modiﬁcations of tau protein
such as phosphorylation [8], O-GlcNAc glycosylation [9] and oxidation
[10] are involved in initiating tau aggregation. Protein–protein interaction
that can induce secondary structure elements in natively unfolded
proteins may also be a candidate for tau beta-sheet formation and
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system such as heat-shock protein function of hsp70/90 [11] and
peptidyl-prolyl-isomerase activity of Pin1 have been implicated in
tau pathology [12,13].
For a better understanding of the molecular mechanisms behind tau
pathologywe screened for tau protein interaction partners,whichmayaf-
fect tau conformation or posttranslational modiﬁcation. Using a cytoplas-
mic interaction screen we identiﬁed axotrophin also named MARCH7 as
tau-interacting protein. Axotrophin belongs to the family of membrane-
associated RING-CH (MARCH) proteins, although no transmembrane
domains for axotrophin are recognizable [14].
Human axotrophin comprises a C4HC3-RING-variant domain in the
C-terminal region similar to zinc binding RING domains of some ubiqui-
tin ligases, also called E3 ligases [15]. Axotrophin is enriched in stem
cells, neuronal cells and spermatids [14,16,17]. Axotrophin null mice
are viable and fertile but show premature neuronal degeneration and
defective development of the corpus callosum [18]. Axotrophin is
functionally linked to the proteins Foxp3 and leukemia inhibitory factor.
Thereby, axotrophin is believed to have an inﬂuence on T cell replica-
tion and immunotolerance with increased axotrophin expression in
immunotolerance [19,20].
Ubiquitination requires the concerted activity of E1, E2 and
E3 enzymes. Ubiquitin is activated by ubiquitin activating enzyme (E1),
and then transferred to an ubiquitin conjugating enzyme (E2) via
thioester linkage. E3 ubiquitin ligases are responsible for speciﬁcity in
substrate recognition either functioning solely as a scaffolding protein
or additionally as a carrier of the activated ubiquitin. Ubiquitination of
substrates can initiate a variety of downstream processes.
Poly-ubiquitination with a K48 linkage is the canonical pathway
for proteasomal degradation of cytoplasmic proteins. Mono- or di-
ubiquitination can induce internalization and trafﬁcking, transcrip-
tion and signal transduction depending on the ubiquitin linkage
and length of the ubiquitin chain [21,22].
For neurodegenerative diseases like AD there is evidence that the
ubiquitin-mediated proteasomal degradation of proteins is disturbed:
1) inclusions of aggregated and ubiquitinated protein are found [23];
2) proteasome activity in AD brains is lower than in age-matched con-
trols [24,25] and 3) mutations in enzymes of the ubiquitination cascade
and ubiquitin are known to appear in neurodegenerative diseases
[26–28].
The aims of this study are (i) the characterization of axotrophin
regarding its subcellular localization and (ii) its potential E3 activity
and (iii) the investigation of the tau axotrophin interaction with tau as
a presumable substrate of axotrophin.
2. Materials and methods
2.1. Plasmids
The pGex-6P1 plasmid was purchased from Amersham Pharmacia
Biotech. The pEGFPC2 and the pDSRed2 plasmid were purchased from
Clontech. For PCR ampliﬁcation of axotrophin and hook3 human fetal
brain marathon-ready cDNA (Clontech) has been used. Other cDNAs
were ampliﬁed from image clones. The integrity of all constructs was
conﬁrmedby automated sequencing. The prk172 tau plasmids are cour-
tesy of M. Goedert, Cambridge, UK. The pGex-Hdm2 plasmid is courtesy
of M. Scheffner, Konstanz, Germany [29].
2.2. Yeast two-hybrid screen
CytoTrap two-hybrid system (Stratagene) was used to identify new
tau interacting proteins. Screening was performed according to the
manufacturer's protocol. Full-length human tau protein 2N4R isoform
cDNA (441aa) was cloned into bait vector pSos for expression of hSos–
tau fusion-protein. CytoTrap human fetal brain cDNA library (Strata-
gene) cloned into target vector pMyr was used for screening. Positiveclones were sequenced. For veriﬁcation and further characterization
of axotrophin interactions the DupLEX yeast two-hybrid assay was per-
formed according to the manufacturer's recommendations (OriGene).
Supplemental Table I summarizes properties of the used constructs. As
negative control for interaction pJG-neg plasmid was used and for posi-
tive interaction control plasmids pBait and pTarget from the DupLEX
system were used.
2.3. Co-immunoprecipitation
Vectors pEG-tau and pJG-axo were introduced into yeast strain
EGY48 (MATα trp1 his3 ura3 leu2:6 LexAop-LEU2). After protein expres-
sionwas induced by galactose cells were harvested and protein extract-
ed in lysis buffer (50mMTris–HCl, pH 7.5, 10mMEDTA, 1mMEGTA, 5%
(v/v) glycerol, 5 μg/mL leupeptin, 5 μg/mL pepstatin, 1 mM PMSF, and
complete protease inhibitor cocktail by Roche). After pre-clearing with
Protein-G Dynabeads (Invitrogen) in immunoprecipitation buffer
(50 mM Tris–HCl, pH 7.5, 300 mM NaCl, 10 mM EDTA, 1 mM EGTA,
5% (v/v) glycerol, 1% (v/v) Triton X-100, 5 μg/mL leupeptin, 5 μg/mL
pepstatin, 1 mM PMSF, and complete) LexA–Tau fusion protein was
precipitated with Protein G-coupled mouse anti-LexA Dynabeads.
Beadswere washed and proteinswere eluted by adding SDS gel loading
buffer and 5 min incubation at 95 °C. Proteins were resolved by SDS-
PAGE followed by Western Blot analysis using rabbit anti-tau antibody
BR134 (1:1000) (1) and rabbit anti-AxoCT antibody, goat anti-rabbit
alkaline phosphatase conjugate (Chemicon) and chemilumines-
cence detection. Anti-AxoCT is a polyclonal afﬁnity-puriﬁed rabbit
antibody directed against the C-terminus of axotrophin. The anti-
body was raised in a rabbit by immunization with KLH-conjugated
peptide ARTLQAHMEDLETSED and isolated by an afﬁnity column
harboring the immobilized peptide.
2.4. Expression and puriﬁcation of recombinant proteins
Overnight colonies of Escherichia coli BL21-CodonPlus (DE3)-RIL
transformed with pGex-AxoRing (aa 549–704), pGex-AxoRingMut
(aa 549–704, C552S, C555S), pGex-KLC1, pGex-PP2Ba, pGex-Hdm2
and tau plasmids prk172-ht40 (441aa, 2N4R isoform), prk172-ht46
(383aa, 0N4R isoform) or prk172-ht37 (410aa, 2N3R isoform) were in-
oculated into 1 L 2xTY containing 100 μg/mL ampicillin and 30 μg/mL
chloramphenicol and grown at 37 °C. When OD600 reached 1.0, protein
expressionwas inducedwith 0.5mM IPTG for 2 to 4 h at 37 °C. The cells
were harvested by centrifugation at 4500 ×g for 10 min at 4 °C. Pellets
of cells transformed with a pGex plasmids were resuspended
in 1/40 volume of PBS with 1 μg/mL leupeptin, 1 mM PMSF and 100 μM
DTT. Pellets of cells transformed with a prk172 construct, expressing an
isoform of human tau, were resuspended in 1/40 volume of lysis buffer
(50mM Tris–HCl, pH 7.4, 5 mM EDTA, 1mM PMSF, 0.1 mMDTT). Resus-
pended pellets were lysed via sonication. To improve solubilization of
protein 1% (v/v) Triton X-100, lysozyme (4000 U/mL) and benzonase
(4 U/mL) were added for 1 h, slowly shaking at 4 °C. Lysate was cleared
by centrifugation at 30,000 ×g for 20 min at 4 °C. GST fusion proteins
KLC1, PP2Ba and Hdm2 were puriﬁed by adding glutathione-sepharose
4B to lysate supernatant for 2 h, slowly shaking at 4 °C. Afterwashing se-
pharose beads several times with PBS, bound protein was cleaved from
GST-tag by adding cleavage buffer (50 mM Tris–HCl, pH 8.0, 150 mM
NaCl, 1 mM EDTA, 1 mM DTT) containing 10 U prescission protease per
mL (GEHealthcare). Eluted proteinswere dialyzed against dialysis buffer
(5 mMMOPS, pH 7.0, 50mMNaCl, 0.1 mM EDTA and 0.1 mM PMSF) for
4 h at 4 °C. All expressed GST axotrophin fragments led to formation of
inclusion bodies and were found in the pellet after clearing the lysate
by centrifugation. For puriﬁcation of GST axotrophin fragments pellet
was washed four times with washing buffer (2 M urea, 2% (v/v) Triton
X-100). Thereafter pellet was extracted in urea buffer (7 M urea,
50 mM Tris–HCl, pH 7.0, 0.2 M NaCl, 50 μM ZnO(Ac)2, 5 mM DTT,
0.5 mM PMSF, 5% (v/v) glycerol) for 2 h and centrifuged at 30,000 ×g
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was solubilized with guanidine buffer (urea buffer with 6 M guanidine
hydrochloride instead of urea) for 2 h and cleared by centrifugation at
30,000 ×g for 30 min at room temperature. Guanidine hydrochloride
supernatant was dialyzed against urea buffer for 4 h and pooled with
urea supernatant followed by a slow sequential buffer exchange to
refolding buffer (50 mM Tris–HCl, pH 7.5, 50 μM ZnO(Ac)2, 5 mM DTT).
To remove precipitates, protein solution was centrifuged at 40,000 ×g
for 20 min at 4 °C. For tau protein puriﬁcation a modiﬁed procedure of
Yoshida and Goedert was used [30]. Brieﬂy, lysis supernatant of E. coli
expressing an isoform of human tau was applied to a diethylaminoethyl
cellulose column(DE52,Whatman) two times. Flow throughwas applied
to a phosphocellulose column (P11, Whatman). Phosphocellulose was
washed with lysis buffer and tau protein was eluted from the column
in 5 mL fractions of 0.1 M, 0.2 M, 0.3 M, 0.4 M and 6× 0.5 M NaCl.
Fractions were analyzed via SDS-PAGE. Cleanest fractions were pooled,
adjusted to a 50% saturation of ammonium sulfate and mixed at 4 °C
for 20 min. Protein precipitate was harvested by centrifugation at
30,000 ×g for 30 min at 4 °C and resuspended in dialysis buffer (5 mM
MOPS, pH 7.0, 50 mM NaCl, 0.1 mM EDTA and 0.1 mM PMSF). To resus-
pended protein 100 mM NaCl and 1% (v/v) β-mercaptoethanol were
added, solution was heated to 100 °C for 10 min and centrifuged at
40,000 ×g for 10 min at 4 °C. Tau protein containing supernatant was
dialyzed against dialysis buffer for 4 h at 4 °C.
2.5. In vitro ubiquitination assay
Enzymes and chemicals for ubiquitination were obtained from
Biomol. Ubiquitination was performed according to the manufacturer's
recommendations, with some modiﬁcations: scaling down the total
reaction volume from 50 μL to 12.5 μL, using twofold volume of E3 en-
zyme (axotrophin) and target protein (tau, PP2Ba, KLC1) and extension
of incubation time from 30–60 min to 3–4 h. Auto-ubiquitination of
axotrophin was performed with each of the provided E2 enzymes and
biotinylated ubiquitin without adding a target protein. Afterwards
ubiquitination mixture was quenched by adding 12.5 μL 2× non-
reducing gel loading buffer and heated for 5 min to 80 °C. Tau protein
ubiquitination was performed using UbcH5c as E2 enzyme, Axotrophin
RING-variant domain as E3 enzyme, ubiquitin or methylated ubiquitin
and biotinylated tau protein. Tau protein was biotinylated on its cyste-
ine residue using maleimide-PEG2-biotin (Pierce). After ubiquitination
tau protein was captured with magnetic streptavidin-beads and heated
in 2× non-reducing gel loading buffer for 5 min to 80 °C. The samples
were separated via SDS-PAGE, blotted to PVDFmembrane and analyzed
by immunolabeling with peroxidase-conjugated extravidin (Sigma-
Aldrich), polyclonal rabbit anti-human tau (Dako), polyclonal rabbit
anti-ubiquitin (Dako) and donkey anti-rabbit IgG linked to peroxidase
(GE Healthcare).
2.6. Binding of ubiquitinated tau to microtubules
Formicrotubule assembly cytoplasmic supernatant of tau knock-out
brain [55] was prepared in assembly puffer (0.1 M MES pH 6.4, 2 mM
EGTA, 0.5 mMMgCl2, 0.1 mM EDTA, complete protease inhibitor cock-
tail, 10 μM UCH-L1 inhibitor, 10 μM UCH-L3 inhibitor, Calbiochem)
and supplemented with 20% glycerol and 1 mM GTP. After addition
of 10 μL ubiquitinated 2N4R tau (ubiquitination performed for 4 h
at 37 °C in the presence of the following enzymes: E1, UbcH5c,
Axotrophin RING-variant domain) or 10 μL non-ubiquitinated 2N4R
tau (ubiquitination mix without UbcH5c) microtubule assembly was
incubated for 60min at 37 °C.Microtubuleswere separated from super-
natant by centrifugation (30,000 ×g, 30 min, 37 °C) through sucrose
cushion and subsequently washed two times with prewarmed BRB80
buffer (80 mM PIPES pH 6.8, 1 mM MgCl2, 1 mM EGTA, 1 mM DTT,
1 mM GTP). Microtubule pellet was disassembled on ice in assembly
buffer and boiled 5 min to remove tubulin by centrifugation. Afteradding 2× gel loading buffer containing 6 M urea to assembly superna-
tant and heatstable microtubule pellet proteins were resolved via SDS-
PAGE followed by Western Blot analysis using polyclonal rabbit anti-
human tau (Dako) and donkey anti-rabbit IgG linked to peroxidase
(GE Healthcare).
2.7. Cell culture and transfection
COS-7 and N2A cells were maintained in DMEM-Ham's F-12 supple-
mented with 10% fetal bovine serum (FBS), non essential amino acids
(Biochrom AG) and 50 μg/mL gentamycin (PAA Laboratories) in a 5%
CO2 environment at 37 °C. For transfection cells were plated in DMEM-
Ham's F12 supplemented with 2% FBS and non essential amino acids
over night. The following axotrophin cDNA fragments cloned into the
Ecl136/SalI site of pEGFPC2: axoFL (aa 1–704), axoN1 (1–625), axoN2
(1–541), axoN3 (1–344), axoC1 (333–704), axoC2 (542–704) were
used. The cells were transfected with pEGFP-axotrophin constructs
with Lipofectamine 2000 (Invitrogen) according to manufacturer's
recommendation. Primary neuronal cultures were prepared from E16
Wistar rat hippocampus using standard protocol [31] and cultured as
described [32] except for seeding cells in neurobasal medium with B27
supplement (Invitrogen), 0.5 mM L-glutamine, 50 μg/mL gentamycin
and 1% FBS for better attachment of cells. Half of the medium was
renewed twice aweek. After 10 days in vitro the cellswere cotransfected
with pRed-Tau and pEGFP-axotrophin using Lipofectamine 2000
(Invitrogen). Cultured and transfected cells were washed with PBS,
ﬁxed with 4% paraformaldehyde and 4% saccharose for 15 min at
room temperature. Fixed cells were permeabilized with PBS and 0.2%
(v/v) Triton X-100 for 10min at room temperature. Nuclei of transfected
COS-7, N2A and rat primary neuronal cells were stained with 4′,6-
diamidino-2-phenylindole dihydrochloride (DAPI, Molecular Probes).
Fluorescence localization was analyzed by laser-scanning confocal
microscope (Zeiss, Heidelberg, Germany).
2.8. Immunohistochemistry
Human temporal cortex (Brodman area 22) and hippocampus of
ﬁve control brains (age 73.6 ± 5.4 years) and ﬁve AD brains Braak
stages II–VI (77.6 ± 5 years) were obtained at autopsy. The post-
mortem diagnosis of AD is based on the recommendations of the Na-
tional Institute on Aging (NIA)-Reagan Institute [33]. Human brain tis-
sue was processed as described [13]. Brieﬂy, endogenous peroxidase
activity was quenched in 1% H2O2 and non-speciﬁc binding sites were
masked by 1 h incubation in a blocking solution containing 2% BSA, 1%
normal donkey serum and 0.01% Triton X-100 in TBS. Free-ﬂoating sec-
tions were incubated overnight (4 °C) with 1 μg/mL anti-AxoCT anti-
body. Immunoreactivity was visualized using the biotin–avidin
system (biotinylated goat anti-rabbit IgG, 1:1000, Jackson
ImmunoResearch Laboratories; biotinylated donkey anti-rabbit Ig,
1:1000; Amersham; streptavidin peroxidase VECTASTAIN ABC Kit, Vec-
tor Laboratories) and 3,3′-diaminobenzidine as chromogen. Tau knock-
out mice (stock no. 004779) [55] and human tau gene transgenic mice,
expressing all human isoforms (stock no. 004808) [56] were obtained
from Jackson Laboratories (Bar Habor), and interbred. The mice were
housed on an artiﬁcial 12 h light/dark cycle under conditions of constant
temperature (22 °C) and humidity (50%). Animals received water and
altromin standard diet ad libitum. Sibling animals at an age of 90 days
of both genotypes were used for analysis. Mouse brain tissue was proc-
essed as described [34] and staining procedure for human tissue
was applied. Immunoreactivity in cytoplasmic and nuclear compart-
ments was semiquantitatively evaluated by measuring an optical
density proﬁle across each cell (20 cells each, on three slices) using
ImageJ. The ratio of cytoplasmic versus nuclear immunoreactivity
was calculated by averaging maximum grayscale in a 1 μm window
in the cytoplasm and the nucleus.
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Frozen human temporal cortices (Brodman area 22, proﬁle of
cases see Suppl. Table II) were homogenized in 7.5 vol/g cytoplasmic
extraction buffer (DPBS pH 7.4 supplemented with, 1 mM MgCl2,
1 mM EDTA, 2 mM EGTA, 25 mM NaF, 10 mM beta-glycerophosphate,
1 mm Na3VO4, 2 μg/mL leupeptin, 0.5 mM calpain inhibitor I and com-
plete protease inhibitor cocktail, Roche) using an ULTRA-TURRAX and
cooling on ice. Cytoplasmic supernatant was obtained from a 60 min
100,000 g centrifugation step at 4 °C and mixed with glycerol to yield10% ﬁnal concentration and stored at −80 °C. The pellet was re-
extracted with 2 vol. using a high-salt buffer (1.3 M LiCl, 30 mM LiCO3,
5 mM Tris/HCl pH 7.4, supplemented with the same components like
the cytoplasmic extraction buffer) with ULTRA-TURRAX homogeniza-
tion. The supernatant obtained from a 60 min 100,000 g centrifugation
step at 4 °C was mixed with glycerol to yield 10% ﬁnal concentration
and stored at −80 °C. 15 μg protein was separated on each lane of a
10% SDS-PAGE and transferred to a PVDF membrane. Immunolabeling
was processed using anti-axotrophin monoclonal antibody BB-8 (Santa
Cruz Biotechnology) and anti-actin monoclonal antibody C4 (Sigma).
Band signal strength was quantiﬁed using densitometric software TINA
2.09g (Raytest).3. Results
3.1. Identiﬁcation of a tau interacting protein, axotrophin
To identify tau interacting proteins, we employed the CytoTrap yeast
two-hybrid assay. Unlike other yeast-based assays this test screens for
interaction in the cytosolic compartment. We used the cDNA of the
longest human tau isoform (2N4R isoform, 441aa) N-terminally fused
to the SOS protein as a bait to screen a cDNA library constructed from
human fetal brain (Fig. 1A). We obtained eleven positives, one of
which was encoding aa 333–704 of Homo sapiens axotrophin/MARCH7
sequence (Gene ID64844). Fig. 1A depicts reconstitution of theCytoTrap
system with growth of yeast cells expressing SOS-tau protein and
axotrophin at non-permissive temperature of 37 °C together with
appropriate positive and negative controls. Sequence analysis displayed
that axotrophin is a protein consisting of 704aa, comprising two main
domains, a C-terminal RING-variant domain and a large N-terminal
part with low sequence complexity but enriched in serine (observed
frequency 20%, expected frequency 8.1% of full length axotrophin) and
arginine (observed frequency 9.7%, expected frequency 4.2%). Full-
length axotrophin can be found from ﬁsh to mammals (Suppl. Fig. 1).
ClustalX sequence alignment reveals that the RING-variant domain is
more conserved during evolution than the N-terminal serine/arginine-
rich domain. In the N-terminal domain basic arginine-rich clusters
such as aa 140–150, 276–300 and 391–411 have a higher degree of con-
servation than intervening sequences (Suppl. Fig. 1, numbering accord-
ing human axotrophin sequence).
To validate the observed interaction between tau and axotrophin
and to localize interacting domains we used the DupLEX yeast two-
hybrid system as an alternative system, where protein–protein interac-
tion has to occur in the nucleus. Therefore full-length axotrophin and N-Fig. 1. Tau interaction with axotrophin in yeast two-hybrid assays. (A) Identiﬁcation of
axotrophin as a tau-interaction partner employing the CytoTrap interaction assay. Trans-
formed cdc25H cells grow under selective conditions (37 °C, galactose-Leu, -Ura), when an
interaction between bait and prey is present (clones 1 and 3 pSOS-tau/pMyr-Axo, clone
6 pSOS-MAFB/pMyr-MAFB positive control). All clones grow at permissive temperature
(25 °C) on galactose-Leu, -Ura. Clones 1, 3: pSOS-Tau + pMyr-Axo, clone 2: pSOS-Tau +
pMyr-MAFB (negative control), clones 4, 5: pSOS-MAFB + pMyr-Axo (negative control),
clone6:pSOS-MAFB+pMyr-MAFB (positive control). (B) Conﬁrmationanddomain analysis
of axotrophin–tau interaction using the DupLEX two-hybrid system. Two different
axotrophin constructs were used as a bait to test for interaction with the prey tau protein.
The axotrophin C-terminal part (pEG-axoCT) with the RING-variant domain comprising aa
552–682 shows a strong interaction with human tau (pJG-tau) indicated by growth on
leucine-deﬁcient medium. The long N-terminal part of axotrophin (pEG-axoNT) comprising
aa 1–538 did not show an interactionwith human tau. The prey protein hook3was used as a
negative control (pJG-neg). The positive control (pos control) was part of the DupLEX two-
hybrid system displaying the interaction of the intracellular domain of the TGFβ-receptor
and the FKBP18. (C) Co-immunoprecipitation of tau and axotrophin after coexpression of
LexA–tau fusion protein and B42–axotrophin fusion protein in yeast cells. Tau protein from
yeast lysate (Ly) was pulled down with matrix-coupled anti-LexA antibody and probed
with tau antibody BR134 (left panel) in the immunoprecipitate (IP) and the supernatant
after immunoprecipitation (SN). The precipitated tau fusion protein is marked with
an arrow. Axotrophin immunoreactivity (right panel) was detected in the anti-tau
immunoprecipitate by the polyclonal anti-AxoCT antibody (see arrow).
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vector aswell as cDNA of the longest human tau isoform into target vec-
tor and transformed into Saccharomyces cerevisiae. Since full-length
axotrophin had autoactivating properties in the LexA-bait vector we
tested different fragments and found that the fragments 1–538 com-
prising the N-terminal region (pEG-axoNT) and aa 552–682 comprising
the RING-variant domain (pEG-axoCT) devoid of large acidic stretches
were not autoactivating. Fig. 1B shows that tau protein is interacting
with the 131aa RING-variant domain of axotrophin but not with the
538aa N-terminal region. This implicates that tau may be a substrate
of the enzymatic activity of the RING-variant domain or a binding part-
ner modulating interaction with E2 enzymes or other substrates.
Next, using full-length axotrophinwe could show in yeast extract that
immunoprecipitating LexA-tau co-precipitates axotrophin (Fig. 1C). Gen-
erally, detection of axotrophin in yeast lysates was complicated by the
short half-life due to auto-ubiquitination (12). This can be seen by the
loss of axotrophin signal in the lysate before (LY) and after precipitation
(SN) (Fig. 1C right panel).
3.2. Axotrophin RING-variant domain acts as E3 ubiquitin ligase in
collaboration with different E2 enzymes in vitro
The axotrophin C4HC3-RING-variant domain occurring in E3 ubiqui-
tin ligases suggests that axotrophin itself may act as E3 ubiquitin ligase.
Therefore, we investigated the potential E3 ubiquitin ligase activity of
axotrophin and its association with relevant E2 enzymes. Due to the
inherent instability of axotrophin in living cells we expressed and puri-
ﬁed recombinant axotrophin C-terminus (aa 548–704) comprising the
RING-variant domain from E. coli inclusion bodies and recovered enzy-
matic activity by a slow protein refolding process. For reconstitution of
the ubiquitin ligase cascade we had to determine which E2 enzyme is
the appropriate interaction partner for axotrophin. We performed a
yeast two-hybrid assay to test interaction with E2 enzymes known toFig. 2. Screening analysis of proteins interacting with the axotrophin C-terminus comprising
the RING-variant domain (aa 552–682). We analyzed E2 enzymes for interaction with
axotrophin and search for other interaction partners by library screening anddual interaction
testing using the DupLEX two-hybrid system. The yeast cells transfected with E2 enzymes
UbcH5a and UbcH5c as activation-domain fusion proteins could grow on leucine deﬁcient
medium (left panel). This points to the UbcH5 family as E2 enzymes cooperating with the
potential E3 ligase axotrophin.Weaker signals were obtained for the neddylation E2 enzyme
Ubc12 and the ubiquitin chain elongating enzyme Ubc13. Two different isoforms of the
protein phosphatase 2B (calcineurin) catalytic subunit (PP2Ba, PP2Bb) and kinesin light
chain (KLC1)were identiﬁedas additional proteins interactingwith theRING-variantdomain
or its ﬂanking sequences.interact with RING-variant domains of other MARCH proteins. Here we
identiﬁed members of UbcH5-family, UbCH12 and UbcH13 as interac-
tion partners (Fig. 2). Therefore, we used UbcH5c as E2 enzyme together
with other components of ubiquitination cascade (Mg-ATP, E1 ligase and
biotinylated-ubiquitin) and with recombinant axotrophin RING-variant
domain to assay for E3 ligase activity. Auto-ubiquitination of axotrophin
detected by extravidin-HRP was used as readout of ligase activity. We
veriﬁed speciﬁcity of the reaction by omission of each component and
mutation of the axotrophin RING-variant domain (Fig. 3A). The linkage
of ubiquitin to wild-type axotrophin RING-variant domain does not
occur if one component of the ubiquitination cascade is absent. Replace-
ment of the two cysteines 552/555 of the CRIC motif of axotrophin with
serine residues should hamper binding of one of the catalytically essen-
tial zinc ions and reduce ligase activity. Although the coordination of the
second zinc is undisturbed the mutated RING-variant domain has a
strongly diminished ligase activity (Fig. 3A, compare lane 1 and lane 6).
These data reveal that axotrophin RING-variant domain acts as an E3
ubiquitin ligase with the feature of auto-ubiquitination.
Having established an in vitro assay of ligase activitywe performed a
more thorough screening for potential E2 enzymes cooperating with
axotrophin. Fig. 3B shows that beside UbcH5b/c, UbcH6 and to a lesser
extent UbcH13 are supporting axotrophin E3 ligase activity because
we observed a linkage of ubiquitin to axotrophin. UbcH1 (E2-25k)
showed only weak activity and all other tested E2 enzymes (UbcH2, 3,
7, 8, 10) were inactive.
3.3. E3 ubiquitin ligase activity of axotrophin RING-variant domain leads to
ubiquitination of tau in vitro
The observation that tau and axotrophin RING-variant domain inter-
act led us ask, whether the E3 ubiquitin ligase activity of the axotrophin
RING-variant domain can induce ubiquitination of tau. To answer this
question we carried out an in vitro ubiquitination assay containing
Mg-ATP, E1, E2 UbcH5c, ubiquitin, axotrophin RING-variant domain as
E3 and human tau isoforms 2N4R, 0N4R, 2N3R as putative E3 ligase
substrates. 2N4R is the longest human tau isoform including two N-
terminal inserts and four microtubule binding domains (441aa). 0N4R
contains four microtubule binding domains but the N-terminal inserts
are absent (383aa). 2N3R includes two N-terminal inserts and three
instead of four microtubule binding domains (410aa). We used these
three human tau isoforms to ascertain if there are differences in exon-
speciﬁc tau ubiquitination by axotrophin RING-variant domain.
When E2 enzyme UbcH5c is not added only the unmodiﬁed tau
band is apparent: for 2N4R tau at 62 kDa, for 0N4R tau at 55 kDa and
for 2N3R tau at 58 kDa (Fig. 3C, lanes 4, 5 and 6). The same occurs
when E3 enzyme axotrophin is omitted (Fig. 3C, lane 7). With a com-
plete ubiquitination cascade we see additional tau bands above the
unmodiﬁed tau band, which are shifted each by about 7–8 kDa. For
2N4R and 0N4R tau up to four such shifted bands above the unmodiﬁed
tau band are visible (Fig. 3C, lanes 1 and 2). The 2N3R isoform exhibits
two shifted bands above the unmodiﬁed tau band (Fig. 3C, lane 3).
These shifted tau bands and some higher molecular weight tau immu-
noreactivity are the result of tau ubiquitination by the axotrophin
RING-variant domain. In a second ubiquitination assaywe usedmethyl-
ated ubiquitin, deﬁcient for ubiquitin chain elongation, and observed a
similar banding pattern compared to unmethylated ubiquitin (Suppl.
Fig. 2, compare lane 1 with lane 3 and lane 2 with lane 4). This result
led us conclude, that the tau isoforms are preferentially mono-
ubiquitinated at multiple sites by axotrophin affecting at least four
lysine residues in four-repeat tau isoforms (0N4R, 2N4R) and two lysine
residues in three-repeat 2N3R isoform. The additional ubiquitination
sites of 0N4R and 2N4R tau in comparison to 2N3R tau allows us to
assume, that these ubiquitination sites are localized in the secondmicro-
tubule binding domain encoded by exon 10, which contains 5 lysine res-
idues. The ubiquitin-linkage to tau protein is conﬁrmed by Western
blottingwith anti-ubiquitin antibody (Fig. 3D). Furthermore, the addition
1532 K. Flach et al. / Biochimica et Biophysica Acta 1842 (2014) 1527–1538of an E4 poly-ubiquitin ligase activity using Ubc13/Mms2 to the
ubiquitination cascade leads to a depletion of the shifted tau bands and
to appearance of high molecular tau species (Fig. 3D), strongly labeled
by the anti-ubiquitin antibody, which preferentially binds to poly-
ubiquitinated proteins.
Control ubiquitination of biotinylated 2N4R tau by recombinant
E3 ligase Hdm2 in the presence of the complete ubiquitination cas-
cade including UbcH5c did not induce tau ubiquitination (data not
shown).In attempt to ﬁndmore potential axotrophin interaction partners or
substrates, we used the LexA-axotrophin RING-variant domain fusion
protein (pEG-axoCT) to screen anAD-related cDNA library andwe iden-
tiﬁed the catalytical subunit of protein phosphatase 2B (PP2Ba, calcine-
urin) and kinesin light chain (KLC1) as positive clones in the yeast two-
hybrid assay (Fig. 2). We puriﬁed both proteins after recombinant
expression in E. coli. Unlike tau protein, no incorporation of ubiquitin oc-
curred in these proteins in the presence of the complete ubiquitination
cascade (Fig. 3C lanes 8, 9 and lanes 10, 11).
1533K. Flach et al. / Biochimica et Biophysica Acta 1842 (2014) 1527–15383.4. Multiplemono-ubiquitination of tau by axotrophin leads to a decreased
microtubule binding capacity of tau
Themultiplemono-ubiquitination of tau by the RING-variant domain
of axotrophin suggests that the microtubule binding afﬁnity of tau is
affected by tau ubiquitination. To verify this assumption we assembled
microtubules in the presence of ubiquitinated or non-ubiquitinated
2N4R tau protein obtained by incubation of tau in the presence of E1,
axotrophin RING-variant domain (E3) and with or without UbcH5c
(E2). Afterwards, the assembly supernatant containing unbound tau
and the pellet containing microtubule-bound tau were separately ana-
lyzed via Western Blot (Fig. 3E). Mono-ubiquitination of 2N4R tau by
the axotrophin RING-variant domain leads to additional tau bands
above the unmodiﬁed tau band at 62 kDa. Ubiquitinated tau protein is
found almost exclusively microtubule-unbound in the supernatant
(Fig. 3E, lane 3). Non-ubiquitinated tau obtained by ubiquitination mix
devoid of UbcH5c preferentially accumulates in the microtubule pellet
(Fig. 3D, lane 4). This result shows that ubiquitin-modiﬁcation of tau
by the axotrophin RING-variant domain leads to a decreased microtu-
bule binding afﬁnity of tau.3.5. Localization of tau and axotrophin in primary neurons, AD brain and
tau knock-out mice
Tau ﬁlaments, a deﬁning feature of several neurodegenerative dis-
eases, have been reported to be ubiquitinated [35]. To analyze a possible
association of axotrophin with tau proteins we prepared an afﬁnity-
puriﬁed rabbit antibody directed against a C-terminal axotrophin
epitope ARTLQAHMEDLETSED conserved in mammals. The speciﬁcity
of this polyclonal anti-AxoCT antibody was veriﬁed byWestern blotting
of axotrophin-transfected cell culture and no cross-reaction with
hyperphosphorylated PHF-tauhas been observed (Fig. 4B). Next,we an-
alyzed axotrophin localization in temporal cortex and hippocampus of
ﬁve controls and AD brains. Immunohistochemistry of human control
brain tissue revealed a predominant nuclear staining of pyramidal
cells of layer III and layer V in the temporal cortex (Fig. 4A CO and
inset c) and other brain areas. In 30% of pyramidal cells axotrophin
immunoreactivity extends into the apical dendrite.
In AD brain tissue the cytoplasmic and nuclear staining of neurons
are largely abolished and tau aggregates such as neuroﬁbrillary tangles
and dystrophic neurites of senile plaques are labeled (Fig. 4A AD inset
a). In addition, hypertrophic astroglial cells are stained (Fig. 4A AD
inset b). Differential extraction of cytoplasmic and nuclear fraction
of axotrophin and quantiﬁcation on Western blot showed a loss ofFig. 3. Reconstitution of axotrophin ubiquitin ligase activity after recombinant expression of the a
ubiquitinating activity of axotrophin RING-variant domain (AxoRing) by Western blotting. We u
ubiquitinating activity of theRING-variant domain is dependent on all components of the ubiquitin
of the axotrophin RING-variant domain is strongly diminished if the ﬁrst two cysteines of the doma
(Bt-Ub) allowed the detection of ubiquitinated proteins by extravidin-HRP. (B) Screening for addit
yeast two-hybrid analysis the UbcH5 family was identiﬁed as the E2 enzymes conferring the highe
dent on UbcH6 and to a lesser extent on Ubc13, already identiﬁed by yeast two-hybrid analysis. U
zymes. (C) Axotrophin RING-variant domain ubiquitinates tau in vitro. Axotrophin RING-variant
human tau isoforms 2N4R, 0N4R, 2N3R or two other axotrophin-interacting proteins KLC1 or PP2
anti-PP2Bwas done. Lane 1 shows that ubiquitination of the longest human tau isoform 2N4R (62
to the unmodiﬁed protein (asterisk). In the control reactions lacking E2 enzyme (lanes 4–6) an
ubiquitination of 0N4R tau isoform, inducing four additional immunoreactive bands. The unmod
(that includes the N-terminal inserts but only three instead of four C-terminal microtubule bindin
in lane 6 runs at 58 kDa. Complete ubiquitination cascadewith E2 UbcH5c leads to additional tau b
ubiquitinated tau (lanes 1–3). Employing KLC1 or PP2Ba in the ubiquitination assay as substrates
lanes 8 and 9 and lanes 10 and 11). Ub: ubiquitin, molecular weight is indicated left in kDa. (D)
Depletion of shifted 2N3R tau bands in the presence of Ubc13/Mms2 (compare lanes 2 and 3) a
antibody (compare lanes 6 and 7), which preferentially labels poly-ubiquitinated tau protei
(E) Microtubule-binding assay of ubiquitinated 2N4R-tau. 2N4R-tau was ubiquitinated in the pre
2 and 3) or left unmodiﬁed by omission of UbcH5 in the reaction mix (lanes 4 and 5). Microtubu
performed and microtubules were pelleted. Lane 1 shows the absence of tau immunoreactivity in
3 and 5) and microtubule pellet (lanes 2 and 4) were detected by anti-tau immunoblotting. Ub
the microtubule pellet.immunoreactivity of 50% and 36.3%, respectively (Fig. 4C). The intracel-
lular co-localization of tau aggregates and axotrophin has been con-
ﬁrmed by immunoﬂuorescence double-labeling and confocal laser
scanning microscopy (Fig. 4D).
To visualize an interaction of tau and axotrophin in living cells we
transfected rat primary neurons with RFP-tau and EGFP-axotrophin.
Confocal laser scanning microscopy shows co-localization of tau and
axotrophin in different neuronal compartments such as cell soma and
at branching points of neurites (Suppl. Fig. 3).
Having shown the axotrophin co-localization with tau aggregates in
AD tissue,we asked how the interaction partner axotrophin is affected if
the other partner, tau protein, is missing. To this end we compared
axotrophin immunohistochemistry in tau knock-out mice with human
tau gene transgenic mice, expressing all human isoforms. Fig. 5A
presents axotrophin immunoreactivity in the cerebellum, where
axotrophin immunoreactivity is detected in neuronal cells. Stellate
cells and purkinje cells are strongly labeled, whereas other cerebellar
neurons such as golgi cells and granule cells are weakly stained. The
absence of tau protein leads to a prominent nuclear localization of
axotrophin in the tau knock-out mice. This contrasts with human tau
gene transgenic mice, where the nuclear compartment of stellate and
purkinje cells remains more spared of axotrophin immunoreactivity,
for quantiﬁcation see Fig. 5B. This leads us to the assumption that
axotrophin may be sequestered by tau in the cytosolic compartment
and this interaction diminishes axotrophin levels.3.6. Subcellular localization of axotrophin
Tau protein is known to occur in the cytoplasmic and nuclear
subcompartments and fulﬁlls different functions in these locations
[57] and detection of endogenous axotrophin in human and mouse
brain tissue revealed also a dual cytoplasmic and nuclear localization
(Figs. 4, 5). Having shown that tau protein is inﬂuencing the intracellu-
lar axotrophin location we asked, which subcellular targeting signals
within the axotrophin amino acid sequence are present.
Transient overexpression of EGFP-tagged full-length axotrophin in
primary neurons and cell lines showed a dual distribution by confocal
laser scanning microscopy (Suppl. Fig. 3 and Fig. 6A1). To study which
axotrophin sequences contribute to the different subcellular localizations,
we transiently expressed different EGFP-tagged axotrophin domains: N-
terminal domains (axoN1 aa 1–625, axoN2 1–541, axoN3 1–344) and
C-terminal domains (axoC1 aa 333–704, axoC2 542–704) in N2A mouse
neuroblastoma cells (Fig. 6) and in COS-7 cells (data not shown).
Fig. 6A1 depicts punctuate cytoplasmic and diffuse nucleoplasmicxotrophin C-terminus comprising the RING-variant domain in E. coli. (A) Testing of E3 auto-
sed the UbcH5c E2 enzyme identiﬁed in the yeast two-hybrid assay to show that E3 auto-
ation cascade such as thepresence of ATP, E1, E2 andubiquitin. E3 auto-ubiquitinating activity
in are substituted by serine residues (m, 552CRIC/552SRIS). The use of biotinylated ubiquitin
ional E2 enzymes capable to reconstitute axotrophin E3 ligase activity. In agreementwith the
st enzymatic activity to axotrophin. In addition axotrophin E3 ligase activity was also depen-
bcH1 had still has residual activity. *: auto-ubiquitinated axotrophin, +: ubiquitinated E2 en-
domain (AxoRing) was incubated with Mg-ATP, E1, E2 UbcH5c, ubiquitin and biotinylated
Ba. After separating proteins via SDS-PAGE, immunoblotting using an anti-tau, anti-KLC1 or
kDa) produced four additional immunoreactive bands each shifted 7–8 kDa apart in addition
d E3 enzyme (lane 7) tau protein isoforms run unmodiﬁed as a single band. Lane 2 shows
iﬁed 0N4R isoform in lane 5 runs at 55 kDa. Ubiquitination of the human 2N3R tau isoform
g repeats) in lane 3 produces only two additional tau bands. The unmodiﬁed 2N3R isoform
ands above the unmodiﬁed tau band, which are shifted each by about 7–8 kDa and represent
does not result in ubiquitin incorporation in these axotrophin-interacting proteins (compare
Ubiquitin chain elongation of mono-ubiquitinated tau protein by E4-ligase Ubc13/Mms2.
nd increase in high-molecular weight tau smear, which is more visible with anti-ubiquitin
n. There is some polyubiquitinated tau protein in the absence of Ubc13/Mms2 (lane 6).
sence of Mg-ATP, E1, E2: UbcH5c, E3: axotrophin RING-variant domain and ubiquitin (lanes
le assembly in the presence of ubiquitinated 2N4R-tau or non-ubiquitinated 2N4R tau was
the microtubule pellet, when no exogenous tau is added. Tau species in supernatant (lanes
iquitinated tau, visible by shifted bands was detected mostly in the supernatant and not in
Fig. 4.Axotrophin immunohistochemistry of human brain tissue. (A) Brain sections (area 22) were labeled with the afﬁnity-puriﬁed anti-AxoCT antibody and visualizedwith DAB/Nickel.
In control brain (CO, lower panel, scale bar: 100 μm) axotrophin is enriched in the nucleus of pyramidal cells in layer III and layer V and to a lesser extent in the cytoplasm and proximal
dendrites of pyramidal cells (inset c, scale bar: 10 μm). In AD brain (AD upper panel, Braak stage V) the preferential nuclear localization is lost and axotrophin immunoreactivity is asso-
ciatedwith pathological tau aggregates in dystrophic neurites around neuritic plaques and neuroﬁbrillary tangles (inset a). In addition hypertrophic astroglial cells are labeled in AD brain
(inset b). (B) Speciﬁcity of afﬁnity-puriﬁed anti-AxoCT antibody. Panel a: COS7 cell lysate transfectedwith pEGFP-axoFL (lane 1), pEGFP-axoC2 (lane 2) and pEGFP (lane 3). Western blot
analysis with anti-AxoCT antibody labels a 100 kDa protein in lane 1 corresponding to the GFP-axotrophin (aa 1-704) fusion protein and a 45 kDa protein in lane 2 corresponding to the
GFP-axotrophin (aa 542-704) fusion protein. Endogenous axotrophinwas undetectable. Panel b: PHF-tau prepared from temporal cortex of ADbrain by the sarcosyl procedurewas probed
with antibodies Tau5/HT7 (lane 1) and anti-AxoCT (lane 2). Three immunoreactive bands corresponding to A68 PHF-tau were strongly labeled by the tau antibodies. The anti-AxoCT
antibodydoesnot cross-reactwith PHF-tau (lane 2). (C) Quantiﬁcation of axotrophin in cytoplasmic and nuclear protein fractions obtained bydifferential protein extraction from temporal
cortex (Brodmann area 22). Equal amount of proteinwas resolved by SDS-PAGE and labeledwith amonoclonal axotrophin antibody. Signal intensity of the 80 kDaprotein bandwas quan-
tiﬁedby densitometry and revealed a signiﬁcant loss of cytoplasmic andnuclear axotrophinprotein inADcases (Student's t-test, **p b 0.01, ***pb 0.001). (D) Co-localization of axotrophin
and neuroﬁbrillary tangles in the hippocampus of AD brain. Axotrophinwas labeled by the polyclonal anti-AxoCT antibody followed by Cy3-linked anti-rabbit secondary antibody (panel
b) and for the detection of tau aggregates monoclonal tau antibody AT8 (1:500) was used followed by Cy2-linked anti-mouse secondary antibody (panel a). Fluorescence labeling was
analyzed by confocal laser scanning microscopy. Axotrophin is colocalized with tau aggregates in hippocampal neurons (panel merge, scale bar: 20 μm).
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Fig. 5. Axotrophin immunohistochemistry in cerebellum of tau knock-out and human tau
gene transgenic mice. (A) Brain sections were labeled with the afﬁnity-puriﬁed anti-
AxoCT antibody and visualized with DAB/Nickel. Cerebellar axotrophin immunoreactivity
is detected inneurons of themolecular layer (mo), Purkinje cell layer (pu) and granule cell
layer (gr). Stellate neurons in the molecular layer and Purkinje cells are strongly labeled,
whereas the granule cell layer exhibits a diffuse staining. Tau knock-out mice reveal a
stronger nuclear axotrophin staining than mice expressing the human tau isoforms
(human tau gene-transgenic mice, scale bar: 30 μm). The insets show that increased
axotrophin staining in tau knock-out mice is due to a stronger axotrophin accumulation
in the nucleus (scale bar 6 μm). (B) Semi-quantitative densitometric analysis of cytoplas-
mic and nuclear axotrophin immunoreactivity. There is a signiﬁcant increase in nuclear
axotrophin localization due to the absence of human tau expression in Mapt knock-out
brains (Mann–Whitney U-test, p ≤ 0.05, n = 3).
1535K. Flach et al. / Biochimica et Biophysica Acta 1842 (2014) 1527–1538distribution of full-length axotrophin in N2A cells. Deletion of the C-
terminal 78aa stretch (axoN1) leads to a pronounced nuclear localiza-
tion (Fig. 6A2). The same localization is found in axoN2,where addition-
ally the RING-variant domain was removed (Fig. 6A3). AxoN1 localizes
to bright, irregularly shaped structures resembling nuclear speckles.
AxoN1 fragment contains 861aa and is too large to be targeted to the
nuclear compartment without active nuclear import. This provokes
the questions, where the nuclear localization signal (NLS) in axoN1
and the nuclear export sequence (NES) in the deleted 78aa fragment
are localized. Using prediction algorithms for NLS no candidate
sequence was found. NES prediction identiﬁed the sequence LNLEDFDright after the RING-variant domain, but this sequence is still included
in axoN1. The skewed amino acid composition of the N-terminal region
rich in serine and arginine resembles serine/arginine-rich (SR) proteins,
which also travel between the nucleus and the cytoplasm. This led us
test whether axotrophin has RNA recognition motifs. RNAbindR [36,
37] predicts two RNA-binding stretches within aa 76–109 and 387–
476 in axotrophin. To verify the signiﬁcance of the RNAbindR prediction,
we expressed axotrophin aa 1–344 (axoN3). AxoN3 is targeted to punc-
tuate nuclear structures too, arguing for a predominant role of the ﬁrst
RNA-binding motif (aa 76–109) for nuclear targeting (Fig. 6A4). In an
opposite approach, we deleted aa 1–332 of axotrophin (axoC1) and
found a diffuse preferential cytoplasmic localization (Fig. 6A5). This em-
phasizes the functional relevance of the ﬁrst RNA-binding motif, of
which loss is not compensated by the remaining RNA-bindingmotif. Ex-
pressing the C-terminus starting with the RING-variant domain (axoC2,
aa 542–704) EGFP-ﬂuorescence reveals a more reticulate cytoplasmic
appearance and in addition can be found at the plasma membrane and
cellular extensions (Fig. 6A6). Fig. 6A7 presents for comparison the
cytoplasmic localization of EGFP protein which also gains access to the
nucleus by diffusion due to its small molecular size.
4. Discussion
The aim of the present study was to ﬁnd tau-interacting proteins,
which can affect tau conformation or posttranslational modiﬁcation.
We have identiﬁed and characterized axotrophin, a protein that
binds and preferentially mono-ubiquitinates tau protein. The tau inter-
action domain of axotrophin is localized to a C-terminal 131aa fragment
containing the RING-variant domain.
Loss of nuclear localization and accumulation of axotrophin in neu-
roﬁbrillary tangle containing neurons of AD brains indicates a relevance
of axotrophin-tau interaction in the pathogenesis of this disease.
Axotrophin is an atypical member of the family of the membrane-
associated RING-CH (MARCH) proteins [15], due to its lack of a trans-
membrane domain and the C-terminal localization of the RING-variant
domain. Viral E3 ligases such as K3 and K5 harboring a RING-variant
domain have been shown to be involved in immune evasion by down-
regulating MHC class I protein [38].
Ubiquitin ligase activity of axotrophin has been demonstrated by Na-
than et al. [14] by the high level of auto-ubiquitination, causing rapid
axotrophin degradation. Decreasing axotrophin auto-ubiquitination by
overexpression of ubiquitin hydrolases USP7 and USP9x increased the
axotrophin level [14]. Because of the lowendogenous levels of axotrophin
we decided to characterize the enzymatic activity by making use of
recombinant axotrophin. We succeeded with recombinant expression
and puriﬁcation of the enzymatically active axotrophin fragment. Testing
different E2 enzymes for axotrophin interaction in a yeast two-hybrid
assay we identiﬁed UbcH5c as a strong interactor, stimulating also
highest axotrophin auto-ubiquitination.
Other E2 enzymes with weaker axotrophin interaction, including
UbcH12 and UbcH13, UbcH6 and UbcH1 (Hip2, E2-25K), were less efﬁ-
ciently recruited by axotrophin in the ubiquitination assay resulting in
low levels of auto-ubiquitination.
Preference of RING-variant domain of viral ubiquitin ligase K3 for
UbcH5 and UbcH13 was elucidated by Dodd et al. [39], whereas two
recent investigations described UbcH1 as also an important axotrophin
activator [14,40].Whereasmostmembrane-boundMARCH proteins are
involved in membrane-receptor downregulation such as MHCI and
MHCII [41], the substrate of axotrophin/MARCH7 ligase activity remains
elusive. Flierman et al. [40] suggest that MHCI may serve as a target of
axotrophin. Recently, Gao et al. [42] found that axotrophin mRNA and
gp190 subunit of leukemia inhibitory factor (LIF) receptor are inversely
correlated, implying that gp190 can be ubiquitinated by axotrophin.We
showed that endogenous and overexpressed full length axotrophin
resides mainly in the nuclear and cytosolic compartments, where it
also can interact with non-membrane bound substrates. We report
1536 K. Flach et al. / Biochimica et Biophysica Acta 1842 (2014) 1527–1538that the microtubule-associated tau protein is such a cytoplasmic
protein, which binds to axotrophin and is a substrate of axotrophin E3
ligase activity. We present several lines of evidence for this interaction,
(i) positive interaction in two different yeast two-hybrid systems,(ii) association found by co-immunoprecipitation, (iii) axotrophin asso-
ciation with tau protein aggregates in Alzheimer's disease, (iv) altered
axotrophin expression/localization in tau knock-out mice and (v) tau
mono-ubiquitination by axotrophin in vitro.
1537K. Flach et al. / Biochimica et Biophysica Acta 1842 (2014) 1527–1538Mono-ubiquitination of tau protein by axotrophin is unlikely to be a
proteasome targeting signal but rather affects afﬁnity of tau to microtu-
bules. Roughly half of the 44 potentially ubiquitin accepting lysine
residues of the 2N4R tau isoform are comprised within the four
microtubule-binding repeats. More ubiquitin was incorporated into
four-repeat tau than three-repeat tau, suggesting that at least one ubiq-
uitin acceptor lysine resides in exon 10. Therefore we assume a tau-
microtubule-afﬁnity regulatory activity of axotrophin,which has a stron-
ger effect on four-repeat than on three-repeat tau protein. We could
show that addition of ubiquitin side-chains prevents tau from binding
to pre-formed microtubules.
The preferential ubiquitination of four-repeat tau by the Hsc70-
interacting protein CHIP was also noted by Hatakeyama et al. [43]. In
contrast to axotrophin, CHIP induces poly-ubiquitination of tau regulat-
ing tau degradation [44,45]. Poly-ubiquitination sites in PHF-tau from
AD brainwere identiﬁed as Lys254, Lys311 and Lys353 [35,46], whereas
sumoylation was conﬁned to Lys340 [47]. Tau poly-ubiquitination is
acknowledged to be a late process in the pathogenesis of Alzheimer's
disease and in an animal model of tau pathology [48,49]. Whereas mul-
tiple mono-ubiquitination of tau by axotrophin could be a physiological
event regulating microtubule binding afﬁnity of tau it may also provide
the basis for ubiquitin chain elongation by so called E4-ligases.
One morphological feature of axotrophin knock-out animals is
reduced axogenesis resulting in the absence of the corpus callosum
[18]. Tau protein is enriched in the axonal compartment, where it func-
tions as a regulator ofmicrotubule dynamics. During process outgrowth
and remodeling a locally reduced microtubule stabilizing activity of tau
is required. This can be accomplished by phosphorylation of the KXGS
motifs in the repeat region of tau protein byMARKkinases [2,50] or pos-
sibly by axotrophin mediated tau ubiquitination. It is speculated that
loss of axotrophin activity may be analogously to prevention of KXGS
phosphorylation leading to microtubule superstability and blocking
process formation.
Beside tau protein, we identiﬁed the catalytic subunit of PP2B and
KLC1 as interaction partners for axotrophin RING-variant domain
by yeast two-hybrid assay. We did, however, not accomplish the
ubiquitination of these proteins by recombinant axotrophin RING-
variant domain. Also, tau ubiquitination by E3 ligase Hdm2 failed. This
emphasizes the speciﬁcity of the ubiquitinating activity of axotrophin to-
wards tau protein. KLC1 interaction with axotrophin in yeast two-hybrid
assay was not only conﬁned to the C-terminal portion containing the
RING-variant domain (pEG-axoCT) but was also detectable to a lesser
extent with the N-terminal axotrophin domain (pEG-axoNT, data not
shown). This interaction may result in intracellular transport of
axotrophin-containing protein complexes giving rise to the granular
and reticular intracellular localization of axoFL and axoN2. In the light of
the recent argument of Lazarov et al. [51] that KLC1 tends to exhibit non-
speciﬁc binding to other proteins, the signiﬁcance of KLC1 interaction
with axotrophin remains unclear. The strong interaction of axotrophin
with both isoforms of PP2B catalytic subunit is intriguing. Axotrophin
mRNA upregulation has been found to be associated with transplanta-
tion tolerance [19]. Since PP2B is a crucial signalingmolecule in regulat-
ing adaptive immunity [52] a potential inhibitory effect of axotrophin on
PP2B activity may present an immune tolerance regulatory mechanism
in addition to LIF receptor downregulation.Fig. 6. Subcellular localization of EGFP–axotrophin fusion proteins. N2A cells were transfectedw
fusion proteins. Confocal images of EGFP ﬂuorescence (A1–A7), nuclear DAPI ﬂuorescence (B1
microscopy. Axotrophin expressed as full length protein has a cytoplasmic and nuclear localizat
to the Golgi apparatus. In addition picture A1 shows two cells (marked with asterisk) with m
predominant nuclear localization in a nuclear speckle-like appearance (A2, B2). This nuclear sp
terminal end such as deleting the RING-variant domain leading to a more heterochromatin as
After deletion the complete C-terminal half yielding a 344aa construct comprising only the ﬁrst
to smaller nuclear subcompartments (A4, B4). In contrast deletion of aa 1–332, removing theﬁrs
localization without the granular appearance observed with full-length axotrophin (A1, B1). F
comprising the RING-variant domain and the C-terminus leads to a cytoplasmic localization o
appearance of solely EGFP in the nuclear and cytoplasmic compartments is shown (A7, B7).Localization of endogenous axotrophin in mouse and human brain
shows the same dual cytoplasmic/nuclear localization like overexpressed
EGFP-tagged full-length axotrophin in cell lines. We found that the N-
terminal portion comprising aa 1–344 targets axotrophin solely to the
nucleus. This nuclear localization may be determined by the ﬁrst RNA-
binding stretch aa 76–109. Although NetNES analysis [53] predicts a
leucine-rich nuclear export signal within aa 611–617 (LNLEDFD) after
the RING-variant domain our analysis shows that a nuclear export signal
must be contained further C-terminal within aa 625–704. The lack of this
nuclear export signal in the EGFP-fusion protein axoN1 (aa 1–625) leads
to a nuclear speckle-like appearance. The localization of axotrophin to
nuclear speckles, a site of the pre-mRNA processing and mRNA export
[54] and sequence similarity of axotrophin to serine/arginine-rich (SR)
proteins argues for a function of axotrophin in RNA maturation and
export. The identiﬁcation of factors controlling the partition between
cytoplasmic and nuclear localization of axotrophin and identiﬁcation of
its nuclear interaction partners remains the target of future work.
5. Conclusions
In summary, we have shown that tau protein interacts with
axotrophin and becomes ubiquitinated by the axotrophin E3 ubiquitin li-
gase activity. Mono-ubiquitination of tau occurs in the microtubule-
binding region and impairs microtubule binding. The dual residency of
axotrophin represents different functions in the cytosol and the nucleus.
We present a novel tau modiﬁcation occurring preferentially on four-
repeat tau proteinwhichmay impact on the pathogenesis of tauopathies.
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